May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study

Abstract

Background: We prospectively assessed the influence of JCV-status on disability's accrual in RRMS patients treated with Natalizumab at two tertiary MS centres, settled in Italy. Methods: Negative binomial model was used to assess the influence of baseline JCV status (positive or negative) treatment on clinical and radiological disease activity during the 24 months' follow-up. Results: One hundred eighty four patients treated with Natalizumab were enrolled (83 JCV +, whilst 101 JCV-). Over the two years of follow-up there was not significant clinical and radiological differences between the two groups.